RxDoctor Payments Data

Thomas Hamilton, MD

Urology · Greenville, SCNPI 1053349555

Payments from drug & device makers

$2,801in general payments, 2019–2025

Across 134 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$759
  • Medtronic$615
  • Boston Scientific$245
  • AbbVie$227
  • Johnson & Johnson$213
  • Astellas Pharma US Inc$160
  • plus $580 from 17 others

What the payments were for

  • Travel & lodging$2037%
  • Food & beverage$2,59893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,801 in reported general payments places this provider in the 40th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$205,757
Medicare patients
464
Services billed
7,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron67$46,121
MyrbetriqMirabegron46$33,006
Mirabegron ErMirabegron12$6,808
Testosterone57$5,122
Tolterodine Tartrate ErTolterodine Tartrate30$2,196
Tamsulosin Hcl195$2,156
Finasteride168$1,641
Potassium Citrate ErPotassium Citrate17$1,296
Alfuzosin Hcl ErAlfuzosin Hcl79$1,230
Bicalutamide41$1,218
Estradiol13$1,160
Oxybutynin Chloride ErOxybutynin Chloride40$610
Trimethoprim12$578
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$317
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$19$46,12167 claims
Astellas Pharma US IncMyrbetriq$160$33,00646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 196 urology providers in South Carolina.

Other urology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →